['ParcelBio', 'Active', 'https://bookface-images.s3.amazonaws.com/small_logos/e3f92a314584614afc78e5eb7b39af9ec261299f.png', ['Y Combinator LogoW24', 'gene-therapy', 'biotech', 'healthcare', 'drug-delivery', 'therapeutics', 'San Francisco'], 'ParcelBio is developing a programmable technology to safely and specifically deliver mRNA to diverse cell types in the body. Our proprietary (nanoparticle-free) technology, which we call ‘STAmP’, stabilizes the mRNA and utilizes an interchangeable, lock-and-key-like targeting mechanism which enables fully customizable mRNA medicines.', '2023', '3', 'San Francisco', {'LinkedIn': 'https://www.linkedin.com/company/parcelbio', 'Twitter': 'Not available', 'Facebook': 'Not available', 'Crunchbase': 'Not available', 'GitHub': 'Not available'}, [{'name': 'David Weinberg', 'socials': {'LinkedIn': 'https://linkedin.com/in/david-e-weinberg', 'Twitter': 'Not available'}}, {'name': 'Chris Carlson', 'socials': {'LinkedIn': 'https://linkedin.com/in/christopher-carlson-', 'Twitter': 'Not available'}}]]

